Abstract:Cis–trans isomerization of protein plays an important role in protein folding, function, and degradation, which is regulated by peptidyl‐proline isomerases (PPIases). The cis P‐tau but not trans P‐tau is resistant to protein dephosphorylation and degradation and also prone to protein aggregation and serves as an early driver of multiple neurodegenerative disease including Alzheimer disease (AD), traumatic brain injury (TBI), chronic traumatic encephalopathy (CTE), and vascular contributions to cognitive impairment and dementia (VCID). Cis P‐tau antibody is the only clinical‐stage therapeutic for AD that has shown the efficacy in animal models of not only AD but also TBI and stroke, which are very early stages of dementia. In this article, we review the role of cis P‐tau in neurodegenerative diseases and its regulation as a potential drug target. A schematic drawing of cis and trans pT231P of tau protein. Cis but not trans P‐tau is induced by multiple stresses and contributes to neurodegenerative diseases. Cis P‐tau is converted into trans P‐tau by Pin1. Conventional tauopathies are a group of disease characterized by tau inclusions in the brains, including Alzheimer's disease (AD), Pick's disease (PiD), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and certain types of frontotemporal dementia (FTD), among which AD is the most prevalent. Extensive post‐translational modifications, especially hyperphosphorylation, and abnormal aggregation of tau protein underlie tauopathy. Cis–trans isomerization of protein plays an important role in protein folding, function, and degradation, which is regulated by peptidyl‐proline isomerases (PPIases). Peptidyl‐prolyl cis–trans isomerase NIMA‐interacting 1 (Pin1), the only PPIase found to isomerize Pro following phosphorylated Ser or Thr residues, alters phosphorylated tau protein conformation at pT231‐P motif. The cis P‐tau but not trans P‐tau serves as an early driver of multiple neurodegenerative disease, encompassing AD, traumatic brain injury (TBI), chronic traumatic encephalopathy (CTE), and vascular contributions to cognitive impairment and dementia (VCID). Cis but not trans P‐tau is resistant to protein dephosphorylation and degradation, and also prone to protein aggregation. Cis P‐tau loses its ability to stabilize microtubule, causing and spreading tauopathy mainly in axons, a pathological process called cistauosis. The conformation‐specific monoclonal antibody that targets only the cis P‐tau serves as a very early diagnosis method and a potential treatment of not only conventional tauopathies but also nonconventional tauopathies such as VCID, with clinical trials ongoing. Notably, cis P‐tau antibody is the only clinical‐stage Alzheimer's therapeutic that has shown the efficacy in animal models of not only AD but also TBI and stroke, which are very early stages of dementia. Here we review the identification and pathological consequences of cis pt231‐tau, the role of its regulator Pin1, as well as the clinical implication of cis pt231‐tau conformation‐specific antibody in conventional and nonconventional tauopathies.

The role of the Pin1-cis P-tau axis in the development and treatment of vascular contribution to cognitive impairment and dementia and preeclampsia

Function and regulation of cis P‐tau in the pathogenesis and treatment of conventional and nonconventional tauopathies

Peptidyl-Prolyl Cis/Trans Isomerase Pin1 and Alzheimer’s Disease

The significance of Pin1 in the development of Alzheimer's disease.

Tauopathies: new perspectives and challenges

Research Progress of the Impact of Pin1 on the Pathogenesis of Alzheimer's Disease

Antibody Against Early Driver of Neurodegeneration Cis P-tau Blocks Brain Injury and Tauopathy

Convergence of presenilin- and tau-mediated pathways on axonal trafficking and neuronal function.

Genetics Pathway-Based Imaging Approaches in Chinese Han Population with Alzheimer’s Disease Risk

Regulation of tau by peptidyl-prolyl isomerases

Tau in neurodegenerative disease

Pathological Role of Peptidyl-Prolyl Isomerase Pin1 in the Disruption of Synaptic Plasticity in Alzheimer's Disease.

Tau-mediated Neurodegeneration and Potential Implications in Diagnosis and Treatment of Alzheimer's Disease

Tau in neurodegenerative diseases: molecular mechanisms, biomarkers, and therapeutic strategies

Genome-wide association study and functional validation implicates JADE1 in tauopathy

Cis P-Tau is Induced in Clinical and Preclinical Brain Injury and Contributes to Post-Injury Sequelae

Pin1 Cysteine-113 Oxidation Inhibits Its Catalytic Activity and Cellular Function in Alzheimer's Disease

Genome-Wide Epistasis Study of Cerebrospinal Fluid Hyperphosphorylated Tau in ADNI Cohort.

Probing tau citrullination in Alzheimer's disease brains and mouse models of tauopathy

Tau in Health and Neurodegenerative Diseases

Genome-Wide Association and Interaction Study on Quantitative Traits of CSF Phosphorylated Tau in ADNI Cohort.